To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Clinical trial NCT03286842 · COMPLETED

Trial details

NCT number: NCT03286842
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HER2-ve Metastatic Breast Cancer Germline BRCA1/2 Mutations Somatic BRCA1/2 Mutations

Start date: 2018-01-17
Primary completion: 2021-10-08
Enrollment: 256

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.